NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

Published on Mar 1, 2016in Lancet Oncology35.386
· DOI :10.1016/S1470-2045(16)00061-9
Caroline J Hall2
Estimated H-index: 2
(National Institute for Health and Care Excellence),
Sally Doss3
Estimated H-index: 3
(National Institute for Health and Care Excellence)
+ 2 AuthorsAndrew Stevens30
Estimated H-index: 30
(National Institute for Health and Care Excellence)
  • References (2)
  • Citations (1)
📖 Papers frequently viewed together
6 Citations
57 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Jesús F. San-Miguel (University of Navarra)H-Index: 109
#2V. HungriaH-Index: 7
Last. Paul G. Richardson (Harvard University)H-Index: 156
view all 45 authors...
Summary Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with placebo, bortezomib, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Methods PANORAMA1 is a multicentre, randomised, placebo-controlled, double-blind phase 3 trial of patients with relapsed or relapse...
401 CitationsSource
#1S. AcasterH-Index: 1
#2Sabine Gaugris (Janssen-Cilag)H-Index: 3
Last. A. J. LloydH-Index: 1
view all 5 authors...
Background While the impact of various treatments on myeloma patients’ health-related quality of life (HRQL) has been reported, the impact of a treatment-free interval (TFI) is currently unclear. The aims of this study were to assess if (1) a TFI is associated with a better HRQL vs. other treatment phases and (2) the length of the TFI influences HRQL.
19 CitationsSource
Cited By1
#1Evangelos Eleutherakis-Papaiakovou (UoA: National and Kapodistrian University of Athens)H-Index: 12
#2Nikolaos Kanellias (UoA: National and Kapodistrian University of Athens)H-Index: 5
Last. M.A. Dimopoulos (UoA: National and Kapodistrian University of Athens)H-Index: 106
view all 6 authors...
Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two prior regimens, including bortezomib and an immunomodulatory agent. In order to further explore its clinical potential, it is evaluated in different combinations in relapsed/refractory and newly diagnos...
2 CitationsSource